A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study will be performed to determine the long-term efficacy of 19.000 BU Oralgen grass
pollen administered daily in patients with grass pollen related allergic rhinoconjunctivitis.